<DOC>
	<DOCNO>NCT00272012</DOCNO>
	<brief_summary>Primary objective : The primary study objective compare efficacy Insulin glulisine , day breakfast vs. Insulin glulisine give day main meal combination insulin glargine + OAD term change HbA1c , baseline endpoint individual patient . The aim study demonstrate two-sided equivalence two therapy regimen receive two different injection time Insulin glulisine . Secondary objective : Secondary study objective compare efficacy safety Insulin glulisine , day breakfast vs. Insulin glulisine give day main meal combination insulin glargine + OAD term : - Change fasting- , pre-/2h-postprandial- , mean daily nocturnal blood glucose ( baseline endpoint ) - Change fast plasma glucose ( baseline endpoint ) - Response rate : Responders patient HbA1c small 7.0 % study endpoint - Insulin dose ( rapid-acting , basal total daily dos ) - Weight , body-mass index - Hypoglycemic event - Adverse event</brief_summary>
	<brief_title>OPAL - Insulin Glulisine , Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 Diabetes mellitus , previously treat combination therapy insulin glargine + OAD ( maximal tolerate dose / approve combination insulin accord local SPCs ( Summary Product Characteristics ) , include use aglucosidase inhibitor ) least 3 month Prescreening HbA1c value greater/equal 7 % smaller/equal 9 % FBG ( Fasting Blood Glucose ) smaller/equal 120 mg/dl ( 6.6 mmol/l ) Women either childbearing potential ( surgically sterile , postmenopausal 2 year ) pregnant agree use reliable contraceptive measure duration study . Reliable contraceptive measure include follow : systemic contraceptive ( oral , implant , injection ) , diaphragm intravaginal spermicide , cervical cap , intrauterine device , condom spermicide . Ability willingness perform blood glucose monitoring use sponsorprovided blood glucose meter subject diary home Exclusion criterion : More two FBG great 120 mg/dl ( 6.6 mmol/l ) measure 5 consecutive day visit II Active proliferative diabetic retinopathy , define application focal panretinal photocoagulation vitrectomy , 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require surgical treatment ( include laser photocoagulation ) Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease make implementation protocol interpretation study result difficult Known impair hepatic renal function History drug alcohol abuse History hypersensitivity insulin insulin analogues excipients Insulin glulisine formulation Treatment investigational drug last month visit I Pregnant breastfeed woman , woman plan become pregnant study Treatment likelihood require treatment study period drug permit clinical study protocol Night shift worker unable comply treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>